Imara Alternatives & Competitors
8 companies similar to Imara — Pioneering therapeutic advancements with innovative solutions for rare genetic h...
Companies similar to Imara
Vera Therapeutics, Inc.
We are a clinical-stage biotechnology company developing treatments that transform patient...
Emmaus Life Sciences, Inc
Improving the lives of people with rare disease.
bluebird bio
Pursuing curative gene therapies to give patients and their families more bluebird days.
Garuda Therapeutics
Creating off-the-shelf, long-term durable blood stem cell therapies
Track all Imara competitors
Get real-time alerts when any of these companies raise funding, hire, or show growth signals.
Orchard Therapeutics - U.S.
Dedicated to transforming the lives of patients with severe and other genetic diseases thr...
Rocket Pharmaceuticals
Seeking gene therapy cures
Promethera Biosciences
Innovative biopharmaceuticals harnessing healthy human liver cells to treat liver diseases...
Elixirgen Therapeutics, Inc.
Reimagine the Power of RNA
About Imara
Imara Inc. is a biotechnology company that is carving a niche in pioneering therapeutic advancements with innovative solutions for rare genetic hemoglobin disorders. Established in 2015, Imara is driven by its slogan, "Pioneering therapeutic advancements with innovative solutions for rare genetic hemoglobin disorders."...
Therapeutics, Genetic Disorders, Hemoglobin, IMR-687, PDE9 Inhibitor, Sickle Cell Disease, Beta-thalassemia, Clinical-stage, Multimodal Mechanism Of Action, Red Blood Cells, White Blood Cells, Adhesion Mediators, Rare Diseases, Innovative Treatments
Frequently Asked Questions
Don't just read about them. Follow them.
BounceWatch watches Imara and millions of other companies. When one raises money, hires quickly or changes its product, we tell you the same day.
Compiled from the BounceWatch company index. We last looked at Imara on 12 Sep 2024. The 8 companies listed here were last checked between 11 Sep 2024 and 3 Jul 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.